3 results on atopic dermatitis
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
PrimaryThe primary objective of this study is to assess the safety and tolerability of BEN2293, administered as multiple topical doses to increasing body surface area (BSA), in patients with mild to moderate AD.SecondaryPharmacokinetics· To…
Primary Objective: To assess the anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who achieve CR/CRhSecondary Objectives:To describe response rate, duration of response, event-free…